ASCO 2024: Immunotherapy for the Treatment of Small Cell Lung Cancer - Episode 5

Predictors of Immunotherapy Response in Limited and Extensive SCLC

July 9, 2024

Ticiana A. Leal, MD, Anne Chiang, MD, PhD, Yale School of Medicine Smilow Cancer Hospital, Afshin Dowlati, MD, Tarita O. Thomas, MD, PhD

Afshin Dowlati, MD, explores which patients with small cell lung cancer experience the most significant benefit from immunotherapy in both limited and extensive stage disease, while also examining potential clinical or molecular characteristics that could serve as predictors of prolonged survival.

EP. 1: Optimizing First-Line Therapy for Limited-Stage Small Cell Lung Cancer

EP. 2: ADRIATIC Trial: Durvalumab, cCRT Timing, and Survival in LS-SCLC

EP. 3: cCRT-to-Durvalumab Interval in Limited Stage LS-SCLC

EP. 4: Examining 3-Year Update Data from the CASPIAN Trial

Now Viewing

EP. 5: Predictors of Immunotherapy Response in Limited and Extensive SCLC

EP. 6: Overcoming Immunotherapy Resistance in Small Cell Lung Cancer

EP. 7: Examining the use of PD-L1 and tTMB in the CASPIAN Trial

EP. 8: Redefining SCLC: Molecular Subtypes and Blood Biomarkers Guide Therapy

EP. 9: Navigating Later-Line Therapy Sequencing in LS-SCLC Progression

EP. 10: DELLphi-301: Platinum Chemotherapy Efficacy in SCLC Survival

EP. 11: Reviewing Ideate-Lung02: Durable Responses in Advanced SCLC

EP. 12: Examining Key Data from DAREON-8

EP. 13: Closing Thoughts and Key Takeaways on Small Cell Lung Cancer

How do we advance the field on which patients with SCLC derive the greatest benefit from IO in both limited stage and extensive stage disease?
Do we yet know which clinical or molecular characteristics might predict extended survival in ES-SCLC, such as platinum sensitivity or PD-L1 expression?
For those who experience extended survival, do you continue immunotherapy and how long is that interval?